全文获取类型
收费全文 | 2913517篇 |
免费 | 244246篇 |
国内免费 | 12940篇 |
专业分类
耳鼻咽喉 | 40037篇 |
儿科学 | 92184篇 |
妇产科学 | 73361篇 |
基础医学 | 479716篇 |
口腔科学 | 77844篇 |
临床医学 | 262194篇 |
内科学 | 496652篇 |
皮肤病学 | 82765篇 |
神经病学 | 250574篇 |
特种医学 | 113589篇 |
外国民族医学 | 92篇 |
外科学 | 457296篇 |
综合类 | 88597篇 |
现状与发展 | 23篇 |
一般理论 | 2100篇 |
预防医学 | 249760篇 |
眼科学 | 66320篇 |
药学 | 196678篇 |
22篇 | |
中国医学 | 8556篇 |
肿瘤学 | 132343篇 |
出版年
2022年 | 22961篇 |
2021年 | 54782篇 |
2020年 | 35009篇 |
2019年 | 58133篇 |
2018年 | 70260篇 |
2017年 | 53438篇 |
2016年 | 58709篇 |
2015年 | 73406篇 |
2014年 | 107484篇 |
2013年 | 172660篇 |
2012年 | 76304篇 |
2011年 | 74433篇 |
2010年 | 112783篇 |
2009年 | 118162篇 |
2008年 | 62013篇 |
2007年 | 62900篇 |
2006年 | 74435篇 |
2005年 | 70067篇 |
2004年 | 72380篇 |
2003年 | 63582篇 |
2002年 | 53806篇 |
2001年 | 74072篇 |
2000年 | 66158篇 |
1999年 | 71664篇 |
1998年 | 62007篇 |
1997年 | 60481篇 |
1996年 | 58264篇 |
1995年 | 53746篇 |
1994年 | 47891篇 |
1993年 | 44835篇 |
1992年 | 47924篇 |
1991年 | 46287篇 |
1990年 | 43907篇 |
1989年 | 43889篇 |
1988年 | 40772篇 |
1987年 | 39942篇 |
1986年 | 37997篇 |
1985年 | 38879篇 |
1984年 | 38546篇 |
1983年 | 36090篇 |
1982年 | 38126篇 |
1981年 | 36374篇 |
1980年 | 34370篇 |
1979年 | 30933篇 |
1978年 | 29765篇 |
1977年 | 27770篇 |
1976年 | 25520篇 |
1975年 | 24177篇 |
1974年 | 23897篇 |
1973年 | 22666篇 |
排序方式: 共有10000条查询结果,搜索用时 9 毫秒
971.
J. Curtis Nickel MD 《Current Prostate Reports》2006,4(3):132-137
Medical therapy is currently the most popular treatment choice for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Because medical therapy of BPH-related LUTS is considered a life-long strategy, short- and long-term cost considerations should play a major role in therapeutic decision-making. The effectiveness in terms of long and short amelioration of symptoms, flow rate, and quality of life are well documented for 5α-blockers and 5α-reductase inhibitors as well as for the gold standard treatment for BPH, transurethral resection of the prostate and minimally invasive therapies. Short-and long-term safety concerns also are well documented for these various treatment options. On the contrary, short- and long-term costs have been less well studied and comparisons depend on the model or analyses undertaken in the few studies available. However, the economic studies based on prospective clinical trial data that have become available throughout the past several decades allow us to rationalize our use of α-blockers, 5α -reductase inhibitors, and combination therapy, taking into consideration age, severity of symptoms, prostate volume, prostate-specific antigen, and the differential response of the various medications (and combination) in selected patients. Based on current studies, 5α -blockers generally provide cost-effective therapy for most patients, whereas 5α-reductase therapy and combination therapy provide cost-effective treatment for patients with larger prostate glands or higher baseline prostate-specific antigen levels. 相似文献
972.
目的探讨剖宫产术后深静脉血栓的护理经验。方法将2003年1月~2005年12月行剖宫产术的产妇76例,采取护理干预,加强饮食指导、抗凝血及溶栓护理。结果70例患者治愈,4例留有后遗症,2例转院,未跟踪报告。结论剖宫产术后易发生深静脉血栓;而高龄、经产、多胎、有产科并发症是其高危因素;应用护理措施进行积极干预,起到较好的预防作用,能保证产妇生命安全,提高产科护理质量。 相似文献
973.
Prof. Dr. H. Delbrück 《Der Onkologe》2006,12(5):451-459
Rehabilitative and palliative measures in the follow-up care of pancreatic cancer patients will remain the dominant medical focus as long as potentially curative measures (recurrence prophylaxis, early detection and therapy of recurrence) have failed to show a significant survival benefit. Rehabilitative measures are possible for patients undergoing potentially curative as well as palliative treatment. Their aim is to alleviate the negative effects of the cancer and its therapy, not only physically, but also psychologically, socially and vocationally. The spectrum of possible somatic handicaps ranges from metabolic disorders, malnutrition and under-nutrition, as well as gastrointestinal symptoms to pain. Assistance in coping with illness, alleviating fears and depression and strengthening compliance are the main areas which are dealt with in psycho-oncology. Assessment of vocational fitness and the capacity to work depends on tumor location, whether R0 or R1 resection has taken place, the extent of pancreas resection, accompanying illnesses, whether or not adjuvant therapy has been given, and the physical condition of the patient 相似文献
974.
Elhaji Youssef A.; Stoica Ileana; Dennis Sheldon; Purisima Enrico O.; Lumbroso Rose; Beitel Lenore K.; Trifiro Mark A. 《Human molecular genetics》2006,15(9):1561
Human Molecular Genetics (2006) 15, 921931; 相似文献
975.
976.
977.
C.A. AMEZCUA H.R. MACDONALD† C.A. LUM W. YI‡ L.I. MUDERSPACH† L.D. ROMAN† & J.C. FELIX† 《International journal of gynecological cancer》2006,16(3):1336-1341
In this study, we examine the prevalence of finding isolated tumor cells (ITCs) in negative lymph nodes of endometrial cancer patients using immunohistochemistry. Seventy-six endometrial cancer patients with lymph nodes histologically negative for metastatic disease were examined. Nodal tissue sections were stained with anticytokeratin antibodies AE-1 and CAM 5.2. Nodes with single or groups of cells (two to four cells) < or =0.2 mm and showing cytokeratin reactivity were positive for ITCs. Findings were compared to features of the primary tumor and patient outcome. ITCs were present in 31 of 1712 lymph nodes. Fifteen (19.7%) patients had ITC-positive nodes. ITCs involved only pelvic nodes in nine cases, only para-aortic nodes in five cases, and pelvic and para-aortic in one case. Tumor in adnexa was the only pathologic feature associated with nodal ITCs (P= 0.0485). All 15 patients with nodal ITCs were alive at follow-up. One (6.7%) patient suffered recurrent disease but was alive at last encounter. Disease recurred in 5 (8.8%) of 57 patients without nodal ITCs. Two are alive without disease, two alive with disease, and one died from her cancer. In summary, a significant proportion of endometrial cancer patients have ITCs detected by immunohistochemistry in histologically negative regional lymph nodes. 相似文献
978.
Matthew J Matasar Ellen K Ritchie Nathan Consedine Carol Magai Alfred I Neugut 《European journal of cancer prevention》2006,15(4):367-370
Despite significant improvements in the prognosis of acute promyelocytic leukemia brought about by therapeutic advances, understanding of the epidemiology of acute promyelocytic leukemia remains limited. Earlier reports have suggested that Hispanics may have an increased incidence of acute promyelocytic leukemia, but no systematic analysis of national data has yet been reported. We performed a retrospective cohort study, using data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute from 1992-2001 in order to compare leukemia incidence rates as a function of race and ethnicity. We identified 709 cases of acute promyelocytic leukemia and analyzed incidence rates by race and sex. Hispanics were not found to have greater lifetime incidence rates than whites, with an incidence relative rate (IRR) of 0.86 that of whites (P=0.17). The age distribution among Hispanics was significantly different from non-Hispanic whites, with greater incidence rates for children ages 1-19 years (IRR=1.9, P=0.02) and adult ages 20-44 years (IRR=1.6, P=0.004). Blacks had lower lifetime incidence rates than non-Hispanic whites (IRR=0.75, P=0.04), Hispanics (IRR=0.64, P=0.007), and Asians (IRR=0.67, P=0.03). Asians did not differ from non-Hispanic whites in lifetime or age-specific incidence rates. These results indicate that while US Hispanics do not have greater lifetime incidence rates of acute promyelocytic leukemia, blacks have lower incidence rates of acute promyelocytic leukemia than Hispanics, non-Hispanic whites, and Asians. 相似文献
979.
980.